Middle East & Africa Adalimumab Market to 2032
Overview
The Middle East & Africa Adalimumab Market is expected to reach a 197.97 USD Billion by 2032 and is projected to grow at a CAGR of 5.36% from 2025 to 2032.
Revenue, 2024 (USD Billion)
149.55
Forecast, 2032 (USD Billion)
197.97
CAGR, 2024 - 2032
5.36%
Report Coverage
Middle East & Africa
Middle East & Africa Adalimumab Market 2018-2032 USD Billion
Middle East & Africa Adalimumab Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 149.55 USD Billion
- Projected Market Size (2032): 197.97 USD Billion
- CAGR (2025-2032): 5.36%
Key Findings of Middle East & Africa Adalimumab Market
- The Middle East & Africa Adalimumab Market was valued at 149.55 USD Billion in 2024.
- The Middle East & Africa Adalimumab Market is likely to grow at a CAGR of 5.36% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Parenteral (SC) in Route of Administration Segment accounted for the largest share of the market with a revenue of 149.55 USD Billion
- The fastest growing segment Biosimilars in Type Segment grew Fastest with a CAGR of 30.42% during the forecast period from 2024 to 2032.
Middle East & Africa Adalimumab Market Scope
Middle East & Africa Adalimumab Market Segmentation & Scope
Population Type
- Children
- Adults
End User
- Others
- Home Healthcare
- Specialty Clinics
- Hospitals
Distribution Channel
- Others
- Direct Tenders
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
Route of Administration
- Oral
- Parenteral (SC)
Type
- Biosimilars
- Biologics
Dosage Strength
- Others
- 10mg/0.1ml
- 20mg/0.4ml
- 80mg/0.8ml
- 40mg/0.4ml
Drug Type
- Generics
- Branded
Indication
- Others
- Non-Infectious Intermediate
- Hidradenitis Suppurativa
- Juvenile Idiopathic Arthritis
- Psoriatic Arthritis
- Ulcerative Colitis
- Crohn's Disease
- Chronic Plaque Psoriasis
- Ankylosing Spondylitis
- Rheumatoid Arthritis
Middle East & Africa Adalimumab Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2020 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 149.55 USD Billion |
| Market Value in 2032 | 197.97 USD Billion |
| CAGR (2025-2032) | 5.36% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Population Type,End User,Distribution Channel,Route of Administration,Type,Dosage Strength,Drug Type,Indication |
Regional Insights:
-
Leading Market (2024-2032): Middle East & Africa, leading in terms of revenue 149.55 USD Billion in 2024
- Key Country: Saudi Arabia, leading in terms of revenue with value of 51.71 USD Billion in 2024.
Segments and Scope
-
Middle East & Africa Adalimumab Market to 2032, By Population Type
- Adults is the largest segment in Middle East & Africa Adalimumab Market to 2032 with a revenue of 112.45 USD Billion in the year 2024.
- Children is the Fastest growing segment in Middle East & Africa Adalimumab Market to 2032 with a Growth rate of 5.07 % in forecast period 2025-2032.
-
Middle East & Africa Adalimumab Market to 2032, By End User
- Hospitals is the largest segment in Middle East & Africa Adalimumab Market to 2032 with a revenue of 81.87 USD Billion in the year 2024.
- Specialty Clinics is the Fastest growing segment in Middle East & Africa Adalimumab Market to 2032 with a Growth rate of 5.19 % in forecast period 2025-2032.
-
Middle East & Africa Adalimumab Market to 2032, By Distribution Channel
- Hospital Pharmacies is the largest segment in Middle East & Africa Adalimumab Market to 2032 with a revenue of 83.60 USD Billion in the year 2024.
- Retail Pharmacies is the Fastest growing segment in Middle East & Africa Adalimumab Market to 2032 with a Growth rate of 5.33 % in forecast period 2025-2032.
-
Middle East & Africa Adalimumab Market to 2032, By Route of Administration
- Parenteral (SC) is the largest segment in Middle East & Africa Adalimumab Market to 2032 with a revenue of 149.55 USD Billion in the year 2024.
- Parenteral (SC) is the Fastest growing segment in Middle East & Africa Adalimumab Market to 2032 with a Growth rate of 5.36 % in forecast period 2025-2032.
-
Middle East & Africa Adalimumab Market to 2032, By Type
- Biologics is the largest segment in Middle East & Africa Adalimumab Market to 2032 with a revenue of 91.95 USD Billion in the year 2024.
- Biosimilars is the Fastest growing segment in Middle East & Africa Adalimumab Market to 2032 with a Growth rate of -4.43 % in forecast period 2025-2032.
-
Middle East & Africa Adalimumab Market to 2032, By Dosage Strength
- 40mg/0.4ml is the largest segment in Middle East & Africa Adalimumab Market to 2032 with a revenue of 69.23 USD Billion in the year 2024.
- 40mg/0.4ml is the Fastest growing segment in Middle East & Africa Adalimumab Market to 2032 with a Growth rate of 5.79 % in forecast period 2025-2032.
-
Middle East & Africa Adalimumab Market to 2032, By Drug Type
- Branded is the largest segment in Middle East & Africa Adalimumab Market to 2032 with a revenue of 91.95 USD Billion in the year 2024.
- Generics is the Fastest growing segment in Middle East & Africa Adalimumab Market to 2032 with a Growth rate of -4.43 % in forecast period 2025-2032.
-
Middle East & Africa Adalimumab Market to 2032, By Indication
- Rheumatoid Arthritis is the largest segment in Middle East & Africa Adalimumab Market to 2032 with a revenue of 55.18 USD Billion in the year 2024.
- Ankylosing Spondylitis is the Fastest growing segment in Middle East & Africa Adalimumab Market to 2032 with a Growth rate of 5.61 % in forecast period 2025-2032.
Middle East & Africa Adalimumab Market Company Share Analysis
Middle East & Africa Adalimumab Market Geographical Sales Distribution, 2018-2032 USD Billion
Middle East & Africa Adalimumab Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Middle East & Africa Adalimumab Market is segmented based on Segmentation Population Type,End User,Distribution Channel,Route of Administration,Type,Dosage Strength,Drug Type,Indication.
Middle East & Africa Adalimumab Market was valued at USD 149.55(Revenue in USD Billion) in 2020.
Middle East & Africa Adalimumab Market is projected to grow at a CAGR of 5.36% during the forecast period of 2024 to 2032.
The Parenteral (SC) segment is expected to dominate the Middle East & Africa Adalimumab Market, holding a largest market share of 149.55 USD Billion in 2024
Middle East & Africa Adalimumab Market Scope
Middle East & Africa Adalimumab Market Segmentation & Scope
Population Type
- Children
- Adults
End User
- Others
- Home Healthcare
- Specialty Clinics
- Hospitals
Distribution Channel
- Others
- Direct Tenders
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
Route of Administration
- Oral
- Parenteral (SC)
Type
- Biosimilars
- Biologics
Dosage Strength
- Others
- 10mg/0.1ml
- 20mg/0.4ml
- 80mg/0.8ml
- 40mg/0.4ml
Drug Type
- Generics
- Branded
Indication
- Others
- Non-Infectious Intermediate
- Hidradenitis Suppurativa
- Juvenile Idiopathic Arthritis
- Psoriatic Arthritis
- Ulcerative Colitis
- Crohn's Disease
- Chronic Plaque Psoriasis
- Ankylosing Spondylitis
- Rheumatoid Arthritis
Frequently Asked Questions
The Middle East & Africa Adalimumab Market is segmented based on Segmentation Population Type,End User,Distribution Channel,Route of Administration,Type,Dosage Strength,Drug Type,Indication.
Middle East & Africa Adalimumab Market was valued at USD 149.55(Revenue in USD Billion) in 2020.
Middle East & Africa Adalimumab Market is projected to grow at a CAGR of 5.36% during the forecast period of 2024 to 2032.
The estimated market value of the Middle East & Africa Adalimumab Market for final year is USD 197.97 (USD Billion).
Middle East & Africa Adalimumab Market Company Profiling
Frequently Asked Questions
The Middle East & Africa Adalimumab Market is segmented based on Segmentation Population Type,End User,Distribution Channel,Route of Administration,Type,Dosage Strength,Drug Type,Indication.
Middle East & Africa Adalimumab Market was valued at USD 149.55(Revenue in USD Billion) in 2020.
Middle East & Africa Adalimumab Market is projected to grow at a CAGR of 5.36% during the forecast period of 2024 to 2032.
The estimated market value of the Middle East & Africa Adalimumab Market for final year is USD 197.97 (USD Billion).
CHOOSE LICENCE TYPE
- 4200.00
- 3500.00
- 2000.00
- 5500.00
- 8500.00
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.